Report : Middle East & Africa Needle-Free Injection Systems Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product (Fillable Needle-free Injectors and Prefilled Needle-free Injectors), Technology (Jet-Based Needle-free Injectors, Spring-Based Needle-free Injectors, Microarray Patch Injectors, and Others), Type (Liquid-Based Needle-free Injectors, Projectile-based Needle-free Injectors, and Powder-Based Needle-free Injectors), Usability (Disposable and Reusable), Site of Delivery (Subcutaneous Injectors, Intramuscular Injectors, and Intradermal Injectors), Application (Vaccine Delivery, Insulin Delivery, Oncology, Pain Management, Dermatology, and Others), and End User (Hospitals, Home Care Settings, Research Laboratories, Pharmaceutical & Biotechnological Companies, and Other End User)
At 16.3% CAGR, the Middle East & Africa Needle-Free Injection Systems Market is speculated to be worth US$ 17.89 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa needle-free injection systems market was valued at US$ 7.25 million in 2022 and is expected to reach US$ 17.89 million by 2028, registering a CAGR of 16.3% from 2022 to 2028. Advantages of using self-injection devices and rising demand for vaccines and biosimilars are the critical factors attributed to the Middle East & Africa needle-free injection systems market expansion.
The use of biosimilars is increasing in the treatment of various ailments such as cancer, hepatitis, diabetes, and several other acute and chronic diseases. With the rising prevalence of these illnesses, the need for biosimilars is also increasing, which is presenting a huge opportunity for pharmaceutical & MedTech manufacturers to develop innovative delivery solutions for biosimilars. As several biosimilars and vaccines are administered through injections, the use of needle free injection technology can provide an easy-to-use and safe method for administering biosimilars without a traditional injection apparatus or skilled staff. Further, many biopharmaceutical manufacturers, vaccine companies, and needle free device manufacturers are entering into strategic acquisitions and collaborations to leverage the growth potential in the vaccine market. Therefore, the launch of effective and safe drug delivery devices using needle free injection technology may boost the Middle East & Africa needle-free injection systems market growth in the near future. For instance, in January 2019, Enesi Pharma and Geovax collaborated on multiple vaccines administered using Implavax needle free injection devices. Furthermore, in August 2021, PharmaJet partnered with Zydus Cadila for the world’s first plasmid DNA COVID-19 vaccine delivery via needle free injection. In addition, the company partnered with Abnova to produce and supply the COVID-19 mRNA vaccine using needle free injection technology. Thus, all these factors encouraging the ease-to-use benefit of these injectors will provide more opportunities for the companies to develop innovative products, which is expected to boost the growth of the Middle East & Africa needle-free injection systems market. Many patients have a phobia for needles, which has led to the low demand for injectable devices; as a result, many companies are now aiming to develop needle free injectors with effective and painless solutions.
On the contrary, higher development costs of needle free injectors compared to conventional injection systems hurdles the growth of Middle East & Africa needle-free injection systems market.
Based on product, the Middle East & Africa needle-free injection systems market is sub segmented into fillable needle-free injectors and prefilled needle-free injectors. The fillable needle-free injectors segment held 63.5% market share in 2022, amassing US$ 4.60 million. It is projected to garner US$ 11.19 million by 2028 to expand at 16.0% CAGR during 2022–2028.
Based on technology, the Middle East & Africa needle-free injection systems market is segmented into jet-based needle-free injectors, spring-based needle-free injectors, microarray patch injectors, and others. The jet-based needle-free injectors segment former held 33.3% of the Middle East & Africa needle-free injection systems market share in 2022, amassing US$ 2.41 million. It is projected to garner US$ 6.14 million by 2028 to expand at 16.9% CAGR during 2022–2028.
Based on type, the Middle East & Africa needle-free injection systems market is segmented into market is segmented into liquid-based needle-free injectors, projectile-based needle-free injectors, and powder-based needle-free injectors. The liquid-based needle-free injectors segment held 70.0% market share in 2022, amassing US$ 5.12 million. It is projected to garner US$ 12.51 million by 2028 to expand at 16.1% CAGR during 2022–2028.
Based on durability, the Middle East & Africa needle-free injection systems market is bifurcated into disposable and reusable. With 59.5% share of the domain, the reusable segment dominated the market in 2022. It accrued US$ 4.31 million in 2022 and is estimated to generate US$ 10.47 million by 2028 to grow at a CAGR of 15.9% over the forecast period.
Based on site of delivery, the Middle East & Africa needle-free injection systems market is segmented into subcutaneous injectors, intramuscular injectors, and intradermal injectors. The subcutaneous injectors segment held 49.8% market share in 2022, amassing US$ 3.61 million. It is projected to garner US$ 9.11 million by 2028 to expand at 16.7% CAGR during 2022–2028.
Based on application, the Middle East & Africa needle-free injection systems market is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology, and others. The vaccine delivery segment held 32.7% market share in 2022, amassing US$ 2.37 million. It is projected to garner US$ 6.08 million by 2028 to expand at 17.0% CAGR during 2022–2028.
Based on end user, the Middle East & Africa needle-free injection systems market is segmented into hospitals, home care settings, research laboratories, pharmaceutical and biotechnology companies, and others. The hospitals segment held 33.5% market share in 2022, amassing US$ 2.43 million. It is projected to garner US$ 6.15 million by 2028 to expand at 16.7% CAGR during 2022–2028.
Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 39.5% of the Middle East & Africa needle-free injection systems market share in 2022. It was assessed at US$ 2.86 million in 2022 and is likely to hit US$ 7.27 million by 2028, exhibiting a CAGR of 16.8% during the forecast period.
Key players dominating the Middle East & Africa needle-free injection systems market are Aijex Pharma International Inc., Crossject, Ferring B.V., and Zealand Pharma A/S, among others.
- In June 2022, NuGen Medical Devices Inc., a leader in needle-free drug delivery, has announced that it will be launching a needle-free injection device specifically designed for domesticated household pets. The PetJet will allow pet owners and veterinarians to safely and quickly inject various types of medication without the fear of hurting their pets with a traditional hypodermic needle.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com